• Solvonis Therapeutics chairman on the future of biotech & neuroscience M&A

  • Jan 30 2025
  • Length: 8 mins
  • Podcast

Solvonis Therapeutics chairman on the future of biotech & neuroscience M&A

Listen for free

View show details

  • Summary

  • Solvonis Therapeutics PLC chairman Dennis Purcell talked with Proactive's Stephen Gunnion about the increasing mergers and acquisitions (M&A) activity in the neuroscience sector. He highlighted how large pharmaceutical companies are shifting their focus to neurological disorders, investing billions in biotech firms working on conditions like schizophrenia, depression, and addiction. Purcell pointed to major deals, such as Pfizer’s $14 billion acquisition of Karuna for its schizophrenia treatment and Eli Lilly’s $9 billion purchase of Intra-Cellular Therapies. He emphasised that pharmaceutical companies are now prioritising "de-risked assets" with clear proof of concept before making acquisitions. Discussing broader trends, Purcell noted that the biotech sector has seen a significant increase in companies over the past decade, rising from 2,000 to 6,000. He believes industry consolidation—whether through big pharma acquisitions or biotech-to-biotech mergers—will drive efficiency and attract more venture capital. Additionally, Purcell addressed advancements in Huntington’s disease treatments, with three promising compounds nearing potential approval. He also sees growing interest in psychedelic-based therapies for mental health conditions, despite some setbacks in 2024. With thousands of ongoing gene therapy trials, Purcell stressed the need for companies to present clear investment cases to attract funding. He remains optimistic that 2025 will bring increased investor interest in neuroscience breakthroughs. 🔔 Subscribe to Proactive’s YouTube channel for more expert insights. Don’t forget to like this video and enable notifications for updates on the latest biotech and pharma news. #Biotech #Neuroscience #PharmaInvesting #MergersAndAcquisitions #GeneTherapy #MentalHealth #BiotechStocks #SolvonisTherapeutics #BigPharma #DrugDevelopment #InvestorInsights
    Show more Show less
Show more Show less

What listeners say about Solvonis Therapeutics chairman on the future of biotech & neuroscience M&A

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available